{"disease":{"id":"tumor-response-rate","name":"tumor response rate"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03910140","title":"TILA-TACE in Treatment of Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03336554","title":"Epigenetic Biomarker for Osteosarcoma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}